Skip to main content
Evidence Snapshot

Serine/threonine-protein kinase PLK1

CHEMBL3024 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:13:36Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3024
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase PLK1 as ChEMBL target CHEMBL3024, mapped to UniProt P53350. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase PLK1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3024
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P53350
Serine/threonine-protein kinase PLK1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Serine/threonine-protein kinase PLK1 matters

As of 2026-09-13

Serine/threonine-protein kinase PLK1 is reviewed as Serine/threonine-protein kinase PLK1 (UniProt P53350); Serine/threonine-protein kinase PLK1 shows late clinical disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 27341 compounds, and 935 assays, with lead potency reaching pChEMBL 10.1.

Disease context
acute myeloid leukemia

Serine/threonine-protein kinase PLK1 shows late clinical disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BI-2536, CAFUSERTIB, ONVANSERTIB.

Start review with acute myeloid leukemia because it currently carries late clinical support. Linked drugs include BI-2536, CAFUSERTIB, ONVANSERTIB, VOLASERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 27341 compounds, and 935 assays for this target. The dominant activity type is IC50. CHEMBL513909 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL513909 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 10.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Serine/threonine-protein kinase PLK1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P53350, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why acute myeloid leukemia is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

27341
Total Compounds
935
Total Assays
5
Approved Drugs
IC50: 1745.0, KI: 878.0, EC50: 62.0, KD: 371.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL513909
 10.1 IC50 Clinical
No preferred name
CHEMBL1908394
 10.0 Kd —
No preferred name
CHEMBL5417495
 9.8 IC50 —
No preferred name
CHEMBL5423881
 9.7 IC50 —
No preferred name
CHEMBL513909
 9.7 Kd Clinical

Approved Drugs

Structure Compound First Approval
FEDRATINIB
CHEMBL1287853
 2019
BRIGATINIB
CHEMBL3545311
 2017
RUXOLITINIB
CHEMBL1789941
 2011
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:13:36Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3024